Adjuvant treatment for stage I HER2+ breast cancer

Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 InhibitionПодробнее

FDA Approves Ribociclib (Kisqali) for Stage 2-3 HR+/HER2- Breast Cancer at Higher Risk of RecurrenceПодробнее

Treatment de-escalation and escalation strategies in HER2-positive breast cancerПодробнее

Trial Demonstrates High Efficacy of Antibody Drug Conjugate in Preventing Early Stage Breast CancerПодробнее

Ribociclib in Early Breast Cancer | NEJMПодробнее

Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and G...Подробнее

Breast Cancer Adjuvant Systemic Therapy Prof. Sarin's Teaching RoundsПодробнее

Dr Nanda on Treatment De-Escalation in HER2+ Breast Cancer and TNBCПодробнее

NATALEE - Addition of Ribociclib to Endocrine Therapy in Adjuvant Settings - Breast Cancer ESMO 2024Подробнее

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

Unanswered questions in the use of adjuvant therapy in early breast cancerПодробнее

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-WynneПодробнее

Optimizing adjuvant therapy: chemotherapy necessity in HR-positive breast cancerПодробнее

BRCA-Positive Early-stage Breast Cancer: Treatment and TestingПодробнее

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancerПодробнее

HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancerПодробнее

Highlights from ESMO 2023 in Breast Cancer – Keynote 756, TROPION-Breast01, Keynote 52Подробнее

NATALEE: ribociclib + NSAI as adjuvant treatment in patients with HR+/HER2− early breast cancerПодробнее

Adjuvant treatment guidelines in post-menopausal women with breast cancerПодробнее

Adding ribociclib to endocrine therapy shows an improvement in invasive DFS in HR+/HER2 BC patientsПодробнее